Experimental study of antitumour activity and effects on leukocyte count of intraperitoneal administration and hyperthermic intraperitoneal chemoperfusion (HIPEC) with dioxadet in a rat model of ovarian cancer

被引：7

作者：

Bespalov, Vladimir Grigorjevich ^{[1
,2
]}

Kireeva, Galina Sergeevna ^{[1
,2
]}

Belyaeva, Olesya Alexandrovna ^{[1
,2
]}

Senchik, Konstantin Yurjevich ^{[1
]}

Stukov, Alexandr Nikolaevich ^{[1
]}

Maydin, Michail Alexandrovich ^{[1
]}

Semenov, Alexandr Leonidovich ^{[1
]}

Gafton, Georgy Ivanovich ^{[1
]}

Guseynov, Konstantin Dzhamiljevich ^{[1
]}

Belyaev, Alexey Mikhailovich ^{[1
]}

机构：

[1] Russian Minist Hlth, NN Petrov Res Inst Oncol, 68 Leningradskaya St, St Petersburg 197758, Russia

[2] ITMO Univ, St Petersburg, Russia

来源：

JOURNAL OF CHEMOTHERAPY | 2016年 / 28卷 / 03期

关键词：

Ovarian cancer; Hyperthermic intraperitoneal chemoperfusion; HIPEC; Dioxadet; Leukocytes; Granulocytes; Lymphocytes; Monocytes; STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; INFECTIOUS COMPLICATIONS; PERIPHERAL-BLOOD; CISPLATIN; PACLITAXEL; SURVIVAL; ONCOLOGY;

D O I：

10.1179/1973947815Y.0000000040

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Survival of rats with advanced ovarian cancer after intraperitoneal (i.p.) administration and hyperthermic intraperitoneal chemoperfusion (HIPEC) with dioxadet and effects of these treatment modalities on leukocyte count were evaluated in two independent series of experiments. Hyperthermic intraperitoneal chemoperfusion with dioxadet (15 mg/kg) provided median survival of rats of 49 days (95% CI 28-70), i.p. administration of dioxadet (1.5 mg/kg) of 28 days (95% CI 16-36; P=0.020). Single i.p. injection of dioxadet caused a significant decrease in total number of leukocytes (17-52%), granulocytes (18-75%), lymphocytes (18-62%) and monocytes (12-46%) in the peripheral blood of tumour-bearing rats compared to untreated animals. After HIPEC with dioxadet, the total number of leukocytes, granulocytes, lymphocytes and monocytes in peripheral blood of rats remained significantly higher than the corresponding values in the group with dioxadet.

引用

页码：203 / 209

页数：7

共 29 条

[1]

Ahmed K, 2013, J PAK MED ASSOC, V63, P504

[2] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[3]

[Anonymous], OPEN CANC J

[4] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[5]

Belyaev AM, 2007, INTRAPERITONEAL CHEM, P254

[6]

Belyaeva O. A., 2014, Voprosy Onkologii (St. Petersburg), V60, P71

[7]

BENSON AB, 1985, CANCER, V56, P1350, DOI 10.1002/1097-0142(19850915)56:6<1350::AID-CNCR2820560622>3.0.CO

[8]

2-1

[9]

Bespalov VG, 2014, VOP ONKOL, V60, P76

[10]

Bespalov VG, 2014, SIB J ONCOL, V62, P14

← 1 2 3 →